Dabrafenib Mesylate

Dabrafenib (GSK2118436, 1 μM) combined with 0.01 μM GSK1120212 suppresses over 90% of cell growth in NRAS mutant clones and effectively reduces S6P phosphorylation in A375 cells¹. Dabrafenib reduces polyphosphate-mediated vascular barrier permeability, decreases inflammatory biomarkers, and inhibits leukocyte adhesion/migration and the activation/production of nuclear factor-κB, tumor necrosis factor-α, and interleukin-6². Dabrafenib also inhibits HMGB1 release and downregulates HMGB1-dependent inflammatory responses, enhancing the expression of cell adhesion molecules in human endothelial cells³.

Dabrafenib (GSK2118436, 1 μM) combined with 0.01 μM GSK1120212 suppresses over 90% of cell growth in NRAS mutant clones and effectively reduces S6P phosphorylation in A375 cells¹.

Dabrafenib reduces polyphosphate-mediated vascular barrier permeability, decreases inflammatory biomarkers, and inhibits leukocyte adhesion/migration and the activation/production of nuclear factor-κB, tumor necrosis factor-α, and interleukin-6².

Dabrafenib also inhibits HMGB1 release and downregulates HMGB1-dependent inflammatory responses, enhancing the expression of cell adhesion molecules in human endothelial cells³.

Dabrafenib treatment results in predominantly immature reproductive tracts with no ovulation signs, similar to controls, but with keratinized and histologically open vaginas⁵.

Dabrafenib treatment results in predominantly immature reproductive tracts with no ovulation signs, similar to controls, but with keratinized and histologically open vaginas⁵.

溶解方案(细胞实验)

DMSO 中的溶解度 : 20.83 mg/mL (33.83 mM; 超声助溶 (<60°C); 吸湿的 DMSO 对产品的溶解度有显著影响，请使用新开封的 DMSO)

溶解方案(动物实验)

"方案 一": "请依序添加每种溶剂：10% DMSO 40% PEG300 5% Tween-80 45% SalineSolubility: ≥ 2.5 mg/mL (4.06 mM); 澄清溶液 此方案可获得 ≥ 2.5 mg/mL（饱和度未知）的澄清溶液。以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；再向上述体系中加入 50 μL Tween-80，混合均匀；然后再继续加入 450 μL 生理盐水 定容至 1 mL。生理盐水的配制：将 0.9 g 氯化钠，溶解于 ddH₂O 并定容至 100 mL，可以得到澄清透明的生理盐水溶液。"

"方案 二": "请依序添加每种溶剂：10% DMSO 90% (20% SBE-β-CD in Saline)Solubility: ≥ 2.5 mg/mL (4.06 mM); 澄清溶液 此方案可获得 ≥ 2.5 mg/mL（饱和度未知）的澄清溶液。以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液 中，混合均匀。2 g SBE-β-CD（磺丁基醚 β-环糊精）粉末定容于 10 mL 的生理盐水中，完全溶解至澄清透明。"

"方案 三": "请依序添加每种溶剂：10% DMSO 90% Corn OilSolubility: ≥ 2.5 mg/mL (4.06 mM); 澄清溶液 此方案可获得 ≥ 2.5 mg/mL（饱和度未知）的澄清溶液，此方案实验周期在半个月以上的动物实验酌情使用。以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。"

"方案 四": "请依序添加每种溶剂：5% DMSO 40% PEG300 5% Tween-80 50% SalineSolubility: 2.5 mg/mL (4.06 mM); 悬浊液; 超声助溶"

"方案 五": "请依序添加每种溶剂：5% DMSO 95% (20% SBE-β-CD in Saline)Solubility: ≥ 2.5 mg/mL (4.06 mM); 澄清溶液"